ID: MRFR/MED/0711-CR | February 2021 | Region: Global | 90 pages
Global Artificial Insemination Market was valued at USD 1,818.29 Million in 2019 and is expected to register a CAGR of 8.6% during the forecast period of 2020 to 2027.
Infertility is a highly prevalent health concern in both males and females. Artificial insemination is a fertility treatment method used to deliver sperm directly to the cervix or uterus in the hopes of getting pregnant. Sometimes, these sperm are washed or prepared to increase the likelihood of conceiving. The growth of the global artificial insemination market is attributed to the growing infertility rate in the world, changing lifestyles. Other factors like developing regulatory scenarios related to artificial insemination and technological advancement in artificial insemination also drive the market. Increasing fertility-related disorders are one of the major factors contributing to the growth of artificial insemination.
An increasing number of medical insurance companies offering coverage for couples of the same sexes is likely to create an opportunity for the global artificial insemination market to grow. The rising awareness about infertility and the possible treatments such as artificial insemination, IVF, and other novel techniques increase the fertility rate for various countries. The government support through reimbursement and co-pay system is anticipated to increase the number of manufacturers entering the market in developing regions.
Artificial insemination involves depositing sperm into the uterus. Artificial insemination costs hundreds of dollars, while IVF costs thousands. Most of the countries in North America and Europe have a high adoption of treatments related to fertility. The number of cycles of artificial insemination covered differs depending on the country. Key players operating in the artificial insemination market are engaged in collaboration with leading companies to optimize the operational efficiency of the production and supply chain. For instance, in July 2019, Vitrolife AB (Sweden) entered into a collaboration agreement with Prime Tech (Japan) to develop and exclusively market the Piezo technique for improved intracytoplasmic sperm injection (ICSI) procedures in humans globally. Similarly, in June 2018, GE Healthcare (US) and Vitrolife AB partnered to improve patient outcomes in assisted reproductive technology. The collaborative agreements by leading players to maintain a global footprint is anticipated to grow the rate of growth for the artificial insemination market.
The growth of the global artificial insemination market can be attributed to the growing rate of infertility globally, changing lifestyles among the population, rise in NHS funds in the fertility market in the biopharmaceutical industry, and large availability of reimbursement. According to the WHO, around 10% of women are affected by infertility, directly or indirectly. In addition, national health institutes estimated that about 12% of reproductive age groups are impacted by infertility. Around 1/3 of infertility is due to the female partner, 1/3 to the male partner, and 1/3 of the mix of issues in the two spouses is unknown. According to the US forecasts, the global fertility rate is likely to fall to 2.4% by 2030 and 2.2% by 2050. The imminent and expanding need for novel therapies to solve infertility-related problems is boosting the manufacturers to develop innovative products. Moreover, an increase in the number of cycles required to conceive has created a huge demand for consumables and devices globally.
Global Artificial Insemination Market Share, By Product Type, 2019 (%)
Source: MRFR Analysis
Global Artificial Insemination Market has been divided based on Type and End User.
On the basis of type, the global artificial insemination market is segmented into intrauterine, intracervical, and intratubal. The increasing prevalence of infertility and technological advancements in artificial insemination are driving the growth of the market. According to the World Health Organization, as of September 2020, around 48 million couples were living with infertility globally. The intrauterine segment accounted for a significant market share of 71.9% in 2019. This large share can be attributed to the large utility as compared to intracervical and intratubal techniques.
On the basis of end user, the global artificial insemination market has been classified as hospitals & clinics, fertility centers, and home-based. The hospitals & clinics segment dominated the global artificial insemination market in 2019. Its large share of 49.0% is attributable to a rising preference for insemination procedure in clinics.
Global Artificial Insemination Market Share, By Region, 2019 (%)
Source: MRFR Analysis
Global Artificial Insemination Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global artificial insemination market owing to the large number of companies operating in the region. In 2019, the Americas accounted for a considerable share of 40.8% of the global artificial insemination market. Other factors attributed to this large market share are government regulations and healthcare expenditure by the countries in the region.
Europe held a substantial share in the global artificial insemination market. The artificial insemination market in Europe is expected to propel during the forecast period, owing to factors such as availability of reimbursement. According to the European Society of Human Reproduction and Embryology’s (ESHRE) fact sheets 4, January 2017, assisted reproduction (ART) is reimbursed in European countries with a variation of 20% to 90% funds supported by the state. In addition, the presence of a highly developed healthcare infrastructure and the rapid adoption of advanced technologies and products are expected to positively impact the Europe artificial insemination market.
The fast growth of the Asia-Pacific region is due to the rising population, increasing number of patients suffering from infertility, the rising awareness about the available treatment options, and availability of various products in the region. For example, Genea Limited (Australia), Hi-tech Solutions (India), Kitazato Corporation (Japan), and other companies are engaged in manufacturing of products like IUI Catheter, disposables such as centrifuge test tube, IUI cannula/catheter, buffers, stylets, and other products.
The market for artificial insemination is growing in the Middle East and Africa (MEA) due to increasing infertility concerns in the middle eastern countries and demand for in-vivo fertilization such as artificial insemination. Furthermore, rising approvals for different treatment opportunities for artificial insemination are propelling the market growth in MEA. In 2019, INVO Bioscience, Inc (US) announced it has entered into commercialization agreements in the African countries with distributors in Nigeria, Uganda, Sudan, and Ethiopia, to distribute the INVOcell system. The commercialization agreement will provide support for the geographical expansion of reach in the region.
The Prominent Players in the Global Artificial Insemination Market are Vitrolife AB, Genea Limited, Rinovum Women’s Health, LLC, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical.
Global Artificial Insemination Market, By Type
Global Artificial Insemination Market, By End User
Global Artificial Insemination Market, By Region
Available Additional Customizations
|Market Size||USD 1,818.29 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors and Trends|
|Segments Covered||Type and End User|
|Geographies Covered||North America, Europe, Asia-Pacific and Rest of the World (RoW)|
|Key Vendors||Vitrolife AB, Genea Limited, Rinovum Women’s Health, LLC, Pride Angel, Hi-tech Solutions, Kitazato Corporation, Fujifilm Irvine Scientific, and Rocket Medical|
|Key Market Opportunities||Medical insurance companies|
|Key Market Drivers||